These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 17692990)

  • 1. NASH and thiazolidinediones: not to be taken lightly.
    Dufour JF
    J Hepatol; 2007 Oct; 47(4):451-3. PubMed ID: 17692990
    [No Abstract]   [Full Text] [Related]  

  • 2. Divergent effects of peroxisome proliferator-activated receptor-gamma ligands in human and mouse nonalcoholic steatohepatitis.
    Caldwell SH; Argo CK
    Hepatology; 2007 Aug; 46(2):285-7. PubMed ID: 17661403
    [No Abstract]   [Full Text] [Related]  

  • 3. Pioglitazone trial for NASH: results show promise.
    Lang L
    Gastroenterology; 2007 Mar; 132(3):836-8. PubMed ID: 17383411
    [No Abstract]   [Full Text] [Related]  

  • 4. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis.
    Balas B; Belfort R; Harrison SA; Darland C; Finch J; Schenker S; Gastaldelli A; Cusi K
    J Hepatol; 2007 Oct; 47(4):565-70. PubMed ID: 17560678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
    Seo YS; Kim JH; Jo NY; Choi KM; Baik SH; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH; Kim A; Yeon JE
    J Gastroenterol Hepatol; 2008 Jan; 23(1):102-9. PubMed ID: 18171348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
    Lehmann DF; Lohray BB
    J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500
    [No Abstract]   [Full Text] [Related]  

  • 7. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN; Tao RY; Tian JY; Liu GT; Ye F
    Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [PPAR gamma ligand pioglitazone as a therapeutic strategy in nonalcoholic steatohepatitis (NASH)].
    Yoneda M; Fujita K; Nakajima A; Wada K
    Nihon Yakurigaku Zasshi; 2006 Oct; 128(4):235-8. PubMed ID: 17038787
    [No Abstract]   [Full Text] [Related]  

  • 9. Review article: the treatment of non-alcoholic steatohepatitis with thiazolidinediones.
    Reynaert H; Geerts A; Henrion J
    Aliment Pharmacol Ther; 2005 Nov; 22(10):897-905. PubMed ID: 16268963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone: more than just an insulin sensitizer.
    Czaja MJ
    Hepatology; 2009 May; 49(5):1427-30. PubMed ID: 19402055
    [No Abstract]   [Full Text] [Related]  

  • 11. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
    Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
    Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glitazones in the treatment of cardiovascular risk factors.
    Bouhlel MA; Chinetti-Gbaguidi G; Staels B
    Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():7-13. PubMed ID: 18001313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of insulin sensitizers in NASH.
    Khashab M; Chalasani N
    Endocrinol Metab Clin North Am; 2007 Dec; 36(4):1067-87; xi. PubMed ID: 17983937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.
    Aithal GP; Thomas JA; Kaye PV; Lawson A; Ryder SD; Spendlove I; Austin AS; Freeman JG; Morgan L; Webber J
    Gastroenterology; 2008 Oct; 135(4):1176-84. PubMed ID: 18718471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiazolidinediones in NASH. An odd couple meant to be?
    Cusi K
    J Clin Gastroenterol; 2009 Jul; 43(6):503-5. PubMed ID: 19384246
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
    Koufany M; Moulin D; Bianchi A; Muresan M; Sebillaud S; Netter P; Weryha G; Jouzeau JY
    Arthritis Res Ther; 2008; 10(1):R6. PubMed ID: 18199331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiazolidinediones as potent inducers of hepatocyte growth factor.
    Ito W; Ueki S; Takeda M; Tanigai T; Kayaba H; Chihara J
    Hepatology; 2010 May; 51(5):1866-7. PubMed ID: 20054867
    [No Abstract]   [Full Text] [Related]  

  • 18. Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer.
    Inamoto T; Shah JB; Kamat AM
    Urol Oncol; 2009; 27(6):585-91. PubMed ID: 19162510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic therapy of non-alcoholic steatohepatitis.
    Ratziu V; Zelber-Sagi S
    Clin Liver Dis; 2009 Nov; 13(4):667-88. PubMed ID: 19818312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.
    Fernandes-Santos C; Carneiro RE; de Souza Mendonca L; Aguila MB; Mandarim-de-Lacerda CA
    Nutrition; 2009; 25(7-8):818-27. PubMed ID: 19268533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.